Merit Medical (MMSI)
NASDAQ:MMSI
Want to see MMSI full AI Analyst Report?
Earnings Data
Report Date
Aug 05, 2026After Close (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
0.96Last Year’s EPS
1.01Same Quarter Last Year
Strong Buy
Based on 10 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call was largely positive: Merit beat revenue and earnings expectations in Q1, delivered the highest first-quarter operating margin in company history, generated stronger free cash flow, and closed strategic acquisitions (Viewpoint, BioLife, C2) that expand high-growth therapeutic markets. Near-term headwinds include a steep OEM decline in the quarter, tariff impacts and uncertainty, divestiture-related revenue drag, a recent Class I recall (managed as immaterial), and Q2 guidance reflecting some margin and EPS pressure. Management reiterated solid full-year guidance and confidence in organic and inorganic growth and emphasized disciplined cost/control efforts and platform alignment.Company Guidance
Revenue Beat and Growth
Total revenue $381.9M, up 7% year-over-year (GAAP) and up 5% on a constant currency basis; results exceeded the high end of prior expectations.
Organic Growth
Organic constant currency growth 2.7% in Q1; excluding divested DualCap revenue, organic constant currency growth was 3.7%.
Profitability Improvement
Non-GAAP operating margin improved to 19.7%, up 47 basis points year-over-year (highest first-quarter operating margin in company history); operating income increased ~10% to $75.3M.
Earnings and Cash Generation
Non-GAAP EPS grew ~9% to $0.94 (Q1) and net income was $56.7M (vs $52.9M prior year); free cash flow $24.7M, up 26% year-over-year.
Strategic M&A and Product Adds
Acquired Viewpoint Medical for $140M (Apr 1) to expand oncology/localization portfolio (OneMark); BioLife and C2 Cryo Balloon acquisitions contributed and exceeded expectations.
Positive Guidance Update
FY2026 guidance updated to GAAP net revenue growth 6.3%–7.8% (constant currency 5.6%–7.0%); non-GAAP diluted EPS guidance $4.10–$4.15, up 5%–8% (includes $0.05 dilution from Viewpoint).
New Reporting and Platform Strategy
Introduced revenue presentation by 'foundational' (~2/3 of 2025 revenue; 6% 3-year CAGR) and 'therapeutic' (~1/3; 11% organic 3-year CAGR) and formalized eight platform operating model to align commercial/R&D.
MMSI Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
MMSI Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Apr 30, 2026 | $68.18 | $62.01 | -9.05% |
Feb 24, 2026 | $82.43 | $79.23 | -3.88% |
Oct 30, 2025 | $83.04 | $87.54 | +5.42% |
Jul 30, 2025 | $82.96 | $84.86 | +2.29% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Merit Medical (MMSI) report earnings?
Merit Medical (MMSI) is schdueled to report earning on Aug 05, 2026, After Close (Confirmed).
What is Merit Medical (MMSI) earnings time?
Merit Medical (MMSI) earnings time is at Aug 05, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is MMSI EPS forecast?
MMSI EPS forecast for the fiscal quarter 2026 (Q2) is 0.96.